BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

ORIONPHARM

All Eps Dividend Board Agm Q1 Q2 Q3

ORIONPHARM 15-Nov-2021

The EPS of Q1 (July '21 to September '21) has significantly decreased compared to the EPS of same period of last year due to no revenue generation from the two of the subsidiary companies namely Orion Power Meghnaghat Limited. and Dutch Bangla power & Associates Ltd. as their contract period has expired. However, the contract renewal with BPDB of the above two subsidiaries is under process.

ORIONPHARM 15-Nov-2021

(Q1 Un-audited): Consolidated EPS was Tk. 0.30 for July-September 2021 as against Tk. 0.82 for July-September 2020; Consolidated NOCFPS was Tk. 1.52 for July-September 2021 as against Tk. 1.46 for July-September 2020. Consolidated NAV per share (including revaluation surplus) was Tk. 80.55 as on September 30, 2021 and Tk. 79.76 as on June 30, 2021. Consolidated NAV per share (excluding revaluation surplus) was Tk. 72.59 as on September 30, 2021 and Tk. 71.79 as on June 30, 2021.

ORIONPHARM 09-Nov-2021

(Continuation news of ORIONPHARM): The Company has reported Consolidated EPS of Tk. 4.01, Consolidated NAV per share (Including Revaluation Surplus) of Tk. 79.76, Consolidated NAV per share (Excluding Revaluation Surplus) of Tk. 71.79 and Consolidated NOCFPS of Tk. 11.07 for the year ended on June 30, 2021 as against Tk. 2.84, Tk. 76.77, Tk. 68.69 and Tk. 8.04 respectively for the same period of the previous year. (end)

ORIONPHARM 05-Jul-2021

(Q3 Un-audited): Consolidated EPS was Tk. 0.95 for January-March 2021 as against Tk. 0.61 for January-March 2020; Consolidated EPS was Tk. 2.98 for July 2020-March 2021 as against Tk. 2.75 for July 2019-March 2020. Consolidated NOCFPS was Tk. 7.52 for July 2020-March 2021 as against Tk. 2.73 for July 2019-March 2020. (cont.)

ORIONPHARM 31-Jan-2021

(Q2 Un-audited): Consolidated EPS was Tk. 1.21 for October-December 2020 as against Tk. 0.97 for October-December 2019; Consolidated EPS was Tk. 2.03 for July-December 2020 as against Tk. 2.14 for July-December 2019. Consolidated NOCFPS was Tk. 2.34 for July-December 2020 as against Tk. 3.11 for July-December 2019. (Cont.)

ORIONPHARM 15-Nov-2020

(Q1 Un-audited): Consolidated EPS was Tk. 0.82 for July-September 2020 as against Tk. 1.17 for July-September 2019; Consolidated NOCFPS was Tk. 1.46 for July-September 2020 as against Tk. 1.96 for July-September 2019. Consolidated NAV per share (including revaluation surplus) was Tk. 77.81 as on September 30, 2020 and Tk. 76.77 as on June 30, 2020. Consolidated NAV per share (excluding revaluation surplus) was Tk. 69.76 as on September 30, 2020 and Tk. 68.69 as on June 30, 2020.

ORIONPHARM 09-Nov-2020

(Cont. of ORIONPHARM): The Company has reported Consolidated EPS of Tk. 2.84, Consolidated NAV per share (Including Revaluation Surplus) of Tk. 76.77, Consolidated NAV per share (Excluding Revaluation Surplus) of Tk. 68.69 and Consolidated NOCFPS of Tk. 8.04 for the year ended on June 30, 2020 as against Tk. 3.77, Tk. 75.19, Tk. 66.98 and Tk. 6.19 respectively for the same period of the previous year. (end)

ORIONPHARM 31-May-2020

(Q3 Un-audited): Consolidated EPS was Tk. 0.61 for January-March 2020 as against Tk. 0.95 for January-March 2019; Consolidated EPS was Tk. 2.75 for July'19-March'20 as against Tk. 3.01 for July'18-March'19. Consolidated NOCFPS was Tk. 2.73 for July'19-March'20 as against Tk. 7.15 for July'18-March'19. (cont.)

ORIONPHARM 28-Jan-2020

(Q2 Un-audited): Consolidated EPS was Tk. 0.97 for October-December 2019 as against Tk. 1.08 for October-December 2018; Consolidated EPS was Tk. 2.14 for July-December 2019 as against Tk. 2.06 for July-December 2018. Consolidated NOCFPS was Tk. 3.11 for July-December 2019 as against Tk. 4.98 for July-December 2018. (cont.)

ORIONPHARM 13-Nov-2019

(Q1 Un-audited): Consolidated EPS was Tk. 1.17 for July-September 2019 as against Tk. 0.98 for July-September 2018; Consolidated NOCFPS was Tk. 1.96 for July-September 2019 as against Tk. 2.62 for July-September 2018. Consolidated NAV per share (including revaluation surplus) was Tk. 76.33 as on September 30, 2019 and Tk. 75.19 as on June 30, 2019. Consolidated NAV per share (excluding revaluation surplus) was Tk. 68.15 as on September 30, 2019 and Tk. 66.98 as on June 30, 2019.

Previous Next page